B&M European Value Shares Decline Following Earnings Warning from Company
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 07 2025
0mins
Source: WSJ
Earnings Outlook: B&M European Value Retail anticipates a decline in adjusted earnings for fiscal 2026 due to price deflation and poor performance in its U.K. business.
Stock Performance: The company's shares dropped 16.5% to 214.50 pence, marking a total decline of 41.4% year to date.
Analyst Views on BME
About BME
BlackRock Health Sciences Trust (the Trust) is a closed-end management investment company. The Trust investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, approximately 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. The Trust is focused on achieving its goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options. The Trust invests in a portfolio of sectors, which include biotechnology, health care equipment and supplies, life sciences tools and services, and pharmaceuticals. BlackRock Advisors, LLC acts as the manager of the Trust.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
